December 13, 2016 7:54am

 

… Regenerative medicine will help us age … better

 

Bad news, we have to start supporting and funding the initiatives as the 1st Century Cures Act is expected by industry analysts to speed up drug development by accelerating the regulatory approval process

 

... And that is a two sided coin; public entities have to recognize investors as their partners and not those to be scammed

 

I answer one question; in which company should investors put, keep and commit their money!

 

Who is in today’s headlights – eight (8) equities, are they a BUY or a SELL – subscribers know!

 

I write in every line that investors need to avoid risks as if I were the first to be hurt if I am wrong!

 

 

 

The sector is being driven by a missing theme - until we get some optimism, the path of least resistance is lower.

 

 

BUY: We should see MANY of “our” universe – JUMP on the new  21st Century Cures Act legislation …

 

Indexes and ETFs: The IWM (+0.34%) is UP while the XLV, IBB and XBI are NOT indicating

Dow futures are UP +0.34% and NASDAQ futures are UP +0.35%

 

U.S. stock index futures pointed to a higher open on Tuesday as traders eyed an upcoming U.S. Fed meeting.

Europe markets were trading higher as investors focused on the upcoming meeting of the Federal Reserve and digested better-than-expected data out from China

Asian markets ended mixed in cautious trade as investors await a widely expected U.S. Fed rate hike this week

 

Data docket: the November read on the NFIB Small Business index ca,e om at 98.4, above October's 94.9. Import prices for November are also scheduled for released at 8.30 a.m. ET.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Monday, POSITIVE on Friday; Thursday wasn’t tracked after NEGATIVE closes on Wednesday and last Tuesday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

·         Monday closed NEGATIVE with 27 decliners, 14 advancers and 2 flats;

·         Friday closed barely POSITIVE with 19 decliners, 20 advancers and 4 flats;

·         Thursday closed without being tracked;

·         Wednesday closed NEGATIVE with 27 decliners, 14 advancers and 2 flats

·         Last Tuesday closed POSITIVE with 17 decliners, 23 advancers and 3 flats;

 

 

Remembering last night’s newsletter, “The stem, cell, gene and regenerative therapy (SCG&RT) sector doesn’t have a cushion in this market, but ... there are still a few spiking up on shallow news and you have others that are just going to keep investors guarded.”

  • The newly passed, 21st Century Cures Act should allow for early patient access to cell therapies, while also creating medical and economic benefits for the U.S. healthcare system.

 

Reiterating, everyone is second guessing what a Trump presidency will mean to the pharma, biotech and its young niece – cell therapy and nephew – regenerative medicine as some in the financial markets think that Trump’s personality is a match to kindling that could spell more growth and possibly inflation.

  • In “our” specific sector, that outlook is dependent on the whether the President elect will address the pricing vagaries of drug and device companies of which “our” universe is dependent to some degree if not now but, to the future!

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

·         The iShares Nasdaq Biotechnology (IBB) closed  Monday down -0.79% and is NOT indicating in Tuesday’s pre-market;

·         The SPDR S&P Biotech ETF (XBI) closed Monday down -1.49% and is NOT indicating in Tuesday pre-market;

·         The Health Care Select Sector SPDR ETF (XLV) closed up +0.48% Monday and is NOT indicating in Tuesday’s pre-market;

·         The iShares Russell 2000 (IWM) closed down -1.06% on Friday and is UP +0.37% in Tuesday’s pre-market

 

                                                                                   

Companies in my headlights:

U.S. Congress passes bill that represents a major opportunity for Regenerative Therapies

21st Century Cures Act is expected by industry analysts to speed up drug development by accelerating the regulatory approval process

We should see MANY of “our” universe – JUMP on this legislation …

  • Applied Genetic Technologies (AGTC)
  • Asterias Biotherapeutics (NYSEMKT: AST)
  • Biostage (BSTG)
  • BioTime (NYSEMKT: BTX)
  • Fate Therapeutics (FATE)
  • Histogenics (HSGX)
  • Intrexon (XON)
  • Organovo (ONVO)

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.